Aspirin improves clinical outcome in all cardiovascular ... in the production of this manuscript. The combined use of antiplatelet drugs acting through different mechanisms is important in ...

Two years after percutaneous coronary intervention, people at risk of a cardiac event had better outcomes with clopidogrel ...

For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

While routine treatment with aspirin plus a second anti-clotting drug, known as dual antiplatelet therapy (DAPT), can prevent ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Compared with patients discharged on dual antiplatelet therapy (DAPT) or oral anticoagulants, those sent home on either aspirin or a P2Y12 inhibitor following implantation with the Amplatzer Amulet ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

While routine treatment with aspirin plus a second anti-clotting drug, known as dual antiplatelet therapy (DAPT), can prevent blood clots, these drugs may increase risk for bleeding, especially ...